<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258245</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000445464</org_study_id>
    <secondary_id>P30CA022453</secondary_id>
    <secondary_id>WSU-D-2869</secondary_id>
    <secondary_id>WSU-HIC-01705M1F</secondary_id>
    <nct_id>NCT00258245</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia</brief_title>
  <official_title>A Phase I Study of Arsenic Trioxide and Ascorbic Acid (ATO/AA) in Combination With Low Dose Velcade-Thalidomide-Dexamethasone (VTD) in Relapsed/Refractory Multiple Myeloma (MM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Ascorbic acid may help arsenic trioxide work better by making cancer
      cells more sensitive to the drug. Bortezomib may stop the growth of cancer cells by blocking
      some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells
      by stopping blood flow to the cancer. Giving arsenic trioxide and ascorbic acid together with
      bortezomib, thalidomide, and dexamethasone may stop the growth of and kill more cancer cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide
      when given together with ascorbic acid, bortezomib, thalidomide, and dexamethasone in
      treating patients with relapsed or refractory multiple myeloma or plasma cell leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the dose-limiting toxicity of arsenic trioxide when given in combination with
           ascorbic acid, bortezomib, thalidomide, and dexamethasone, particularly in terms of
           sensory neuropathy, in patients with relapsed or refractory multiple myeloma or plasma
           cell leukemia.

      Secondary

        -  Determine the overall response rate, complete response rate, and response duration in
           patients treated with the maximum tolerated dose of this regimen.

        -  Determine whether the addition of arsenic trioxide and ascorbic acid to the treatment
           regimen (beginning in course 2) increases NFKB inhibition in these patients during
           courses 2 and 3 compared to course 1.

      OUTLINE: This is a multicenter, dose-escalation study of arsenic trioxide.

        -  Induction therapy: Patients receive bortezomib IV over 3-5 seconds and dexamethasone IV
           or orally on days 1, 4, 8, and 11 and oral thalidomide once daily on days 1-21 (course
           1). For course 2 and all subsequent courses, patients receive arsenic trioxide IV over
           1-2 hours, ascorbic acid IV over 15 minutes, bortezomib IV over 3-5 seconds, and
           dexamethasone IV or orally on days 1, 4, 8, and 11 and thalidomide once daily on days
           1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable
           toxicity. Patients who achieve a plateau in response proceed to maintenance therapy.

        -  Maintenance therapy: Patients receive oral dexamethasone every other day and oral
           thalidomide once daily in the absence of disease progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of arsenic trioxide until the maximum
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2
      of 3 or 2 of 6 patients experience dose-limiting toxicity.

      PROJECTED ACCRUAL: A total of 24 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if arsenic trioxide and ascorbic acid at doses up to 0.25 mg/mg/dose can be given in combination with reduced-dose dexamethasone, bortezomib and thalidomide without dose limiting toxicity, especially sensory neuropathies.</measure>
    <time_frame>Days 1, 4, 8 &amp; 11 of each 21 day cycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the Overall Response Rate (ORR), Complete Response Rate (CRR), and Response Duration (RD) in patients treated with the Maximally Tolerated Dose (MTD) of this regimen.</measure>
    <time_frame>at cycle 2 and 6 weeks after</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine if addition of Arsenic Trioxide[AT]/Ascorbic Acid (Vit C)[AA] starting in cycle 2 of treatment increases NF-kappa-B [NFKB] inhibition in cycles 2 and 3 compared to cycle 1.</measure>
    <time_frame>At baseline and 1 hour after the first dose of Bortezomib in cycles 1, 2, and 3</time_frame>
    <description>Peripheral blood samples are to be obtained at baseline, and 1 hour after the first dose of Bortezomib in cycles 1, 2, and 3 for Pharmacodynamic studies</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP d 1, 4, 8, 11; Arsenic Trioxide [AT] (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11; Thalidomide (Thalomid)- 50 mg/day by mouth (PO); Dexamethasone (Decadron)- 40 mg/d IVPB or by mouth (PO) d 1, 4, 8, 11; Ascorbic Acid (Vit C)- 1000 mg IVPB p Arsenic Trioxide (ATO) days 1, 4, 8, 11; Aspirin (ASA)- 325 mg by mouth (PO) every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ascorbic acid</intervention_name>
    <description>Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>All Day C CR</other_name>
    <other_name>Ascot</other_name>
    <other_name>C Complex</other_name>
    <other_name>C-500</other_name>
    <other_name>C-500-Gr</other_name>
    <other_name>C-Time</other_name>
    <other_name>Cecon</other_name>
    <other_name>Cemill 1000</other_name>
    <other_name>Cemill 500</other_name>
    <other_name>Centrum Singles-Vitamin C</other_name>
    <other_name>Cevi-Bid</other_name>
    <other_name>N Ice with Vitamin C</other_name>
    <other_name>Special C</other_name>
    <other_name>Sunkist Vitamin C</other_name>
    <other_name>Vicks Vitamin C Drops</other_name>
    <other_name>Vitamin C TR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
    <description>Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Trisenox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Velcade®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Dexasone</other_name>
    <other_name>Decadron</other_name>
    <other_name>Diodex</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Maxidex</other_name>
    <other_name>Dexamethasone Sodium Phosphate</other_name>
    <other_name>Dexamethasone Acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
    <description>Thalidomide (Thalomid) - 50 mg/day by mouth (PO)</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin - 325 mg by mouth (PO) every day</description>
    <arm_group_label>Bortezomib, AT, Thalidomide, Dexamethasone, Vit C, ASA</arm_group_label>
    <other_name>Acuprin 81</other_name>
    <other_name>Anacin Aspirin Regimen</other_name>
    <other_name>Ascriptin</other_name>
    <other_name>Ascriptin Enteric</other_name>
    <other_name>Aspergum</other_name>
    <other_name>Aspidrox</other_name>
    <other_name>Aspir-Low</other_name>
    <other_name>Aspir-Mox</other_name>
    <other_name>Aspir-trin</other_name>
    <other_name>Aspirtab</other_name>
    <other_name>Bayer Aspirin</other_name>
    <other_name>Bufferin</other_name>
    <other_name>Buffex</other_name>
    <other_name>Easprin</other_name>
    <other_name>Ecotrin</other_name>
    <other_name>Ecpirin</other_name>
    <other_name>Empirin</other_name>
    <other_name>Entaprin</other_name>
    <other_name>Entercote</other_name>
    <other_name>Fasprin</other_name>
    <other_name>Genacote</other_name>
    <other_name>Gennin-FC</other_name>
    <other_name>Genprin</other_name>
    <other_name>Halfprin</other_name>
    <other_name>Magnaprin</other_name>
    <other_name>Med Aspirin</other_name>
    <other_name>Migralex</other_name>
    <other_name>Miniprin</other_name>
    <other_name>Minitabs</other_name>
    <other_name>Norwich Aspirin</other_name>
    <other_name>Ridiprin</other_name>
    <other_name>Sloprin</other_name>
    <other_name>St. Joseph Aspirin</other_name>
    <other_name>Uni-Buff</other_name>
    <other_name>Uni-Tren</other_name>
    <other_name>Valomag</other_name>
    <other_name>Zero-Order Release</other_name>
    <other_name>Zorprin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed multiple myeloma (MM) or plasma cell leukemia meeting 1 of
             the following criteria:

               -  Relapsed or refractory disease after treatment with prior effective therapy

               -  Exhibited &lt; a partial response to the last therapy

          -  Measurable disease, defined by 1 of the following:

               -  Serum M protein ≥ 1.0 g/dL

               -  Urine M-protein ≥ 500 mg/24 hours

               -  Plasmacytoma with bidimensional measurements on CT scan or MRI (each axis ≥ 1 cm)

          -  Previously treated with ≥ 1 induction chemotherapy regimen for MM

          -  No known CNS involvement by multiple myeloma

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod or SWOG 0-2 OR

          -  Karnofsky 60-100%

        Life expectancy

          -  More than 12 weeks

        Hematopoietic

          -  WBC ≥ 1,500/mm^3

          -  Absolute neutrophil count ≥ 1,000/mm^3

          -  Platelet count ≥ 80,000/mm^3

          -  Hemoglobin ≥ 8.5 g/dL

          -  No history of heparin-induced thrombocytopenia

               -  Low blood counts allowed if marrow is heavily infiltrated by multiple myeloma

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit normal (ULN)

          -  AST and ALT ≤ 2.5 times ULN

        Renal

          -  Creatinine ≤ 2.5 mg/dL

        Cardiovascular

          -  QTc &lt; 480 msec on EKG in the presence of serum potassium ≥ 4.0 mEq/dL and serum
             magnesium ≥ 1.8 mg/dL

          -  LVEF ≥ 55% by ECHO or MUGA

          -  No prior deep vein thrombosis, unless on concurrent anticoagulation

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No history of ventricular arrhythmia

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after
             completion of study treatment

          -  No history of allergic reactions or severe adverse reactions attributed to compounds
             of similar chemical or biological composition to study drugs

          -  No other malignancy in the past 2 years except adequately treated nonmelanoma skin
             cancer or carcinoma in situ of the cervix

          -  No peripheral neuropathy ≥ grade 2

          -  No ongoing or active infection requiring IV antibiotics

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other uncontrolled illness

          -  Controlled HIV disease allowed as long as there are no associated comorbid
             complications

          -  No active peptic ulcer disease

          -  No other condition that would confer a high risk of bleeding complications

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  More than 4 weeks since prior thalidomide or lenalidomide for MM

          -  Prior autologous or allogeneic stem cell transplant for MM allowed

          -  Concurrent hematopoietic growth factors (e.g., epoetin alfa, filgrastim [G-CSF]) for
             MM allowed

        Chemotherapy

          -  See Disease Characteristics

          -  More than 4 weeks since prior arsenic trioxide for MM

        Endocrine therapy

          -  More than 4 weeks since prior corticosteroids for MM

        Radiotherapy

          -  More than 4 weeks since prior therapeutic radiotherapy (e.g., to plasmacytomas)

               -  Palliative radiotherapy for painful symptomatic lytic skeletal lesions allowed
                  within the past 4 weeks

        Surgery

          -  Not specified

        Other

          -  More than 4 weeks since prior cytotoxic agents or other therapy (e.g., bortezomib) for
             MM

          -  More than 30 days (or 5 half-lives) since prior investigational agents

          -  Concurrent bisphosphonates for MM allowed

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A. Zonder, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-1379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Aspirin, aluminum hydroxide, magnesium hydroxide drug combination</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

